2 minute read
Supplier News & Innovations
Medtronic India launches MiniMed 780G for diabetes management
INDIA – Medtronic, a global leader in healthcare technology has launched MiniMed 780G, an automated insulin delivery system in India.
MiniMed 780G is a next-generation closed-loop insulin pump system for the treatment of type 1 diabetes in patients aged seven to eighty. The system automates the delivery of both basal insulin and correction boluses every five minutes, making it easier for diabetics to avoid highs and lows.
The MiniMed 780G system personalizes glucose goals with an adjustable target setting as low as 100 mg/dL — lower than any other advanced hybrid closed-loop system — and is designed to help stabilize blood sugar levels and improve glucose control. The system is part of a new Medtronic insulin pump portfolio that includes smartphone connectivity via Bluetooth technology.
Users and their care partners can now view real-time glucose data and trends on compatible iOS and Android smartphones via apps.
Abbott introduces upgraded digital health app for neurostimulation
USA – Abbott Laboratories, an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois has launched an updated version of its Neurosphere MyPath digital health app.
The medtech company has created an advanced app with enhanced functionality to assist doctors in closely monitoring their patients as they test Abbott neurostimulation devices to relieve chronic pain. Abbott’s digital health app is available for both Apple and Android devices, and it provides a doctor, their staff, and the patient with a unified view of patient-reported results at each stage of the treatment journey.
Meanwhile, Abbott has received FDA approval for its latest 3D cardiac mapping platform, which is intended to help physicians target abnormal heart rhythms. The EnSite X EP system inserts a catheter into the heart to map out the regions of the cardiac muscle where unsteady electric pulses can cause irregular heartbeats, and then guides surgeons through ablation procedures to treat those areas.
FDA okays BD’s newest molecular diagnostics machine and its first test
USA – BD (Becton, Dickinson and Company) a global leader in medical technology, has announced the FDA approval of its new, fully automated, high-throughput infectious disease molecular diagnostics platform in the United States.
On the BD Cor platform, the MX system joins the previously cleared PX and GX instruments. Overall, the platform is intended to fully automate the workflow in molecular diagnostics labs, from sample processing to result delivery—all at a relatively fast and large scale.
Along with the release of the MX component, BD was given the goahead to release the instrument’s first assay: a three-in-one test that detects the most common nonviral sexually transmitted infections, including chlamydia, gonorrhea, and trichomoniasis.
When combined with the BD Cor PX and GX systems, the MX platform can accept 1,700 samples for testing. It can run for up to seven hours without interruption before needing more samples or reagents to continue processing. Thanks to a combination of robotics and automated algorithms, the system can generate up to 1,000 test results every 24 hours, largely without the need for hands-on supervision from lab workers.
